Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00978055 | Fasting Study of Liothyronine Sodium Tablets (50 Mcg) to Cytomel® Tablets (50 Mcg) | PHASE1 | COMPLETED | 31 | — | — | Oct 1, 2007 | Dec 1, 2007 | Sep 16, 2009 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Liothyronine Sodium Tablets, 50 mcg |
| 2 | ACTIVE_COMPARATOR | Cytomel® Tablets, 50 mcg |
| Name | Type | Description |
|---|---|---|
| 1: Liothyronine Sodium Tablets | DRUG | Liothyronine Sodium Tablets, 50 mcg 2 x 50 mcg, single-dose, fasting |
| 2: Cytomel® Tablets | DRUG | Cytomel® Tablets, 50 mcg 2 x 50 mcg, single-dose, fasting |
Inclusion Criteria: * healthy males and/or non-pregnant, non-lactating females, 18 years and older * able to swallow medication Exclusion Criteria: * institutionalized subjects * history of any significant disease * use of any prescription or OTC medications within 14 days prior to start of study...